iBio Secures $26mln in Funding from Frazier Life Sciences Management and Existing Investors.

iBio, Inc. expects to receive $26 million in funding through a securities purchase agreement with institutional investors, including Frazier Life Sciences Management. The funding will be used for undisclosed purposes and is expected to close on January 13, 2026, subject to customary conditions. The shares and pre-funded warrants were offered under Section 4(a)(2) of the Securities Act of 1933 and Regulation D.